Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Alcohol-Associated Liver Disease
NCT04736966Phase 1Completed
- Sponsor
- University of California, San Diego
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of guselkumab in alcohol-associated liver disease (ALD) (3 arms), sponsored by University of California, San Diego. Primary endpoint: Safety and Tolerability of Guselkumab at 48 weeks. Started Mar 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
alcohol-associated liver disease (ALD)
Beyond the preview
Go deeper on NCT04736966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736966.